Enteral nutrition in people receiving allogeneic stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized phase II trial enrolling 112 patients with blood cancers or related disorders who plan an allogeneic HSCT. Participants are assigned to standard nutrition management or enteral nutrition via a feeding tube starting on day +1 for at least 7 days, typically until engraftment. The primary goal is to see if enteral feeding reduces severe gut-related GVHD (stage 3-4) by day +100, with several secondary outcomes including other GVHD measures, weight and muscle changes, functional status, quality of life, hospital stay, and engraftment timing. Assessments will include GVHD grading, ADL/IADL, Fried Frailty, and FACT-BMT among others.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of a hematological condition or serious blood disorder
* Patient planned for an allogeneic hematopoietic stem cell transplant
* Any conditioning regimen or graft source

Exclusion Criteria:

* Uncorrected anatomical deformity of the nose, nasopharynx, esophagus, or stomach that could prevent proper placement of a nasogastric tube.
* Chronic gastrointestinal conditions causing malabsorption or need for nutritional supplementation, e.g., celiac disease, short gut syndrome, chronic use of total parental nutrition or enteral nutrition for 3 or more months. Uncorrected anatomical deformity may include any known significant deviated nasal septum, large nasal polyps or other masses, or nasal or oropharyngeal trauma.

Where it's running

• Fred & Pamela Buffet Cancer Center
  Omaha, Nebraska, United States Recruiting

Study contacts

• Principal investigator: Michael Haddadin, MD — University of Nebraska
• Study coordinator: Krishna vamsi Gottipati, MS
• Email: krgottipati@unmc.edu
• Phone: (402) 5593518

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tracking invasive fungal infections after allogeneic hematopoietic stem cell transplant

  We will follow people who had an allogeneic stem cell transplant to see how often serious fungal infections occur and which clinical factors predict them.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07569055

• Ruxolitinib plus decitabine intensified conditioning for AML patients having allogeneic stem cell transplant

  This trial will see if adding ruxolitinib and decitabine to standard busulfan-based conditioning before allogeneic HSCT lowers relapse in high‑risk AML patients in first complete remission (CR1).

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07101588

• Detecting lung diseases early after stem cell transplants

  This study is testing new ways to spot lung problems early in kids and adults who have had a stem cell transplant to help them get better treatment.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06093867

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• Venetoclax plus azacitidine consolidation vs standard chemotherapy before stem cell transplant in high-risk AML

  This study tests whether a venetoclax-containing consolidation helps newly diagnosed high-risk AML patients who have CR/CRi after VA induction to improve outcomes before allo-HSCT.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07425782

• Ivosidenib maintenance after allogeneic stem cell transplant for IDH1-mutant AML

  This trial tests whether taking ivosidenib versus a placebo after allogeneic stem cell transplant can prevent relapse in adults with IDH1-mutant AML.

  Recruiting at 7 sites Phase 2 Massachusetts General Hospital · Atlanta, Georgia and 6 other locations · NCT06707493

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.